National Commission: Recommends MHRA AI Healthcare Staged Authorisations

• The National Commission into the Regulation of AI in Healthcare published recommendations on September 10, 2026, to strengthen AI regulation in UK healthcare.
• A key proposal is for the MHRA to introduce "staged authorisations" for new AI models, allowing supervised real-world deployment before full approval.
• The Commission, established by the MHRA in September 2025, gathered evidence from over 12,000 people, including international experts.
• Public engagement revealed broad support for AI in healthcare, provided there are strong safety standards, human oversight, and transparency.
• The recommendations aim to make the UK a leading environment for AI innovation, safe testing, and patient engagement, while ensuring patient safety and public trust.

A cornerstone of these recommendations is the proposal for the Medicines and Healthcare products Regulatory Agency (MHRA) to implement a system of MHRA AI healthcare staged authorisations for new AI models.

The National Commission into the Regulation of AI in Healthcare has unveiled a comprehensive set of recommendations designed to bolster the oversight of artificial intelligence within the UK's health sector. Published on September 10, 2026, the report outlines a forward-thinking approach aimed at ensuring that AI innovations are adopted safely, keep pace with rapid technological advancements, and consistently earn public trust. A cornerstone of these recommendations is the proposal for the Medicines and Healthcare products Regulatory Agency (MHRA) to implement a system of MHRA AI healthcare staged authorisations for new AI models.

This innovative staged authorisation AI models framework is likened to a provisional licensing system for learner drivers, where new AI technologies would initially be deployed under stringent supervision and strict controls. This initial phase would allow developers to demonstrate the real-world safety and performance of their models in a controlled environment before they are granted full regulatory approval. The Commission believes this phased approach will not only provide UK patients with early access to promising new AI solutions but also ensure that potential risks are meticulously managed throughout the deployment lifecycle, establishing a robust UK AI medical device approval pathway.

The independent Commission, which was established by the MHRA in September 2025, spent a year gathering extensive evidence to inform its recommendations. This monumental undertaking involved engaging with over 12,000 individuals, including patients, the general public, clinicians, healthcare leaders, industry stakeholders, and technology developers. This made it the largest public engagement initiative ever conducted in the UK concerning the regulation of healthcare technology. The Commission's diverse expertise included international contributors from countries such as the USA and Singapore, bringing a global perspective to the challenge.

Further insights were provided by in-depth deliberative research conducted by the Health Foundation with members of the UK public, published concurrently with the Commission's report. This extensive public engagement revealed broad support for the integration of AI into healthcare, contingent upon clear conditions: robust safety standards, meaningful human oversight in AI applications, and transparent communication regarding the use of AI in patient care. The Commission's recommendations directly address these public priorities, aiming to create a MHRA AI regulatory framework that balances innovation with patient protection and public confidence, thereby guiding NHS AI adoption guidelines.

The overarching vision articulated by the Commission is to cultivate a future healthcare system that is increasingly technology-enabled yet remains fundamentally people-centred. The report emphasizes that AI is already making a tangible difference within the NHS, assisting in the early detection of serious health conditions like strokes and skin cancers, and enhancing clinical efficiency through voice-enabled technologies. The recommendations are designed to expand these benefits to a greater number of patients, positioning the UK as a premier global hub for AI innovation.

Specifically, the National Commission Regulation AI Healthcare aims to make the UK the ideal environment for innovators to develop and safely test AI, for healthcare professionals to effectively utilise these tools, and crucially, for patients to confidently engage with AI as part of their care. This ambitious goal underscores the need for a dynamic and modern regulatory framework that not only accelerates the safe adoption of AI but also safeguards patients and fosters widespread professional and public confidence. The proposed staged authorisation AI models are central to achieving this balance, ensuring healthcare AI compliance UK standards evolve with technology.

Lawyers and compliance officers advising on UK healthcare AI should prepare for the MHRA's proposed 'staged authorisation' framework, which will introduce new, potentially phased, approval and oversight requirements for AI models in medical devices, impacting development and market entry strategies. This signals a shift towards dynamic, real-world performance monitoring for AI in healthcare.

Source: Original reporting via GOV.UK